Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

The Lancet Oncology

Volumn 17, Issue 9, 2016, Pages 1248-1260

  Ascierto, Paolo A ^a   McArthur, Grant A ^b,c   Dréno, Brigitte ^d   Atkinson, Victoria ^e   Liszkay, Gabrielle ^f   Di Giacomo, Anna Maria ^g   Mandalà, Mario ^h   Demidov, Lev ⁱ   Stroyakovskiy, Daniil ^j   Thomas, Luc ^k,l   de la Cruz Merino, Luis ^m   Dutriaux, Caroline ⁿ   Garbe, Claus ^o   Yan, Yibing ^p   Wongchenko, Matthew ^p   Chang, Ilsung ^p   Hsu, Jessie J ^p   Koralek, Daniel O ^p   Rooney, Isabelle ^p   Ribas, Antoni ^q   Larkin, James ^r   more..

^a NATIONAL CANCER INSTITUTE   (Italy)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITÉ DE NANTES   (France)

^e PRINCESS ALEXANDRA HOSPITAL   (Australia)

^f NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^g UNIVERSITY HOSPITAL OF SIENA   (Italy)

^h PAPA GIOVANNI XXIII HOSPITAL   (Italy)

ⁱ N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^j Moscow City Oncology Hospital 62   (Russian Federation)

^k UNIVERSITÉ LYON 1   (France)

^l CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^m HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

ⁿ HÔPITAL SAINT ANDRÉ   (France)

^o UNIVERSITY OF TÜBINGEN   (Germany)

^p GENENTECH INC   (United States)

^q UNIVERSITY OF CALIFORNIA   (United States)

^r INSTITUTE OF CANCER RESEARCH   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; B RAF KINASE; COBIMETINIB; CREATINE KINASE; GAMMA GLUTAMYLTRANSFERASE; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; PLACEBO; PROTEIN S6; VEMURAFENIB; ANTINEOPLASTIC AGENT; AZETIDINE DERIVATIVE; BRAF PROTEIN, HUMAN; GDC-0973; INDOLE DERIVATIVE; PIPERIDINE DERIVATIVE; SULFONAMIDE; TUMOR MARKER;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIGEN EXPRESSION; ARTICLE; ATELECTASIS; BRAF GENE; CLOSTRIDIUM DIFFICILE INFECTION; COMA; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENE MUTATION; HEART ARREST; HEART FAILURE; HUMAN; HYPERTRANSAMINASEMIA; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDIAN SURVIVAL TIME; METASTATIC MELANOMA; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINOPATHY; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; CANCER STAGING; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; FOLLOW UP; GENETICS; MELANOMA; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; MUTATION; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SECONDARY; SKIN NEOPLASMS; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZETIDINES; BIOMARKERS, TUMOR; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDOLES; MALE; MELANOMA; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; NEOPLASM STAGING; PIPERIDINES; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; SULFONAMIDES; SURVIVAL RATE; YOUNG ADULT;

EID: 84994499942     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)30122-X     Document Type: Article

References (32)

1. 1 Davies, H, Bignell, GR, Cox, C, et al. Mutations of the BRAF gene in human cancer. Nature 417 (2002), 949–954.
2. 2 Curtin, JA, Fridlyand, J, Kageshita, T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 353 (2005), 2135–2147.
3. 3 Chapman, PB, Hauschild, A, Robert, C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364 (2011), 2507–2516.
4. 4 Hauschild, A, Grob, JJ, Demidov, LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380 (2012), 358–365.
5. V600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 15 (2014), 323–332.
6. 6 Hauschild, A, Grobb, J, Demidov, L, et al. An update on overall survival (OS) and follow-on therapies in BREAK, a phase II randomized trial:dabrafenib(D) dacarbazine (DTIC) in patients (PTS) with BRAF V600E. Ann Oncol, 25(suppl 1), 2015 abstr 1092PD.
7. 7 Johannessen, CM, Boehm, JS, Kim, SY, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468 (2010), 968–972.
8. 8 Villanueva, J, Vultur, A, Lee, JT, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18 (2010), 683–695.
9. 9 Poulikakos, PI, Persaud, Y, Janakiraman, M, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480 (2011), 387–390.
10. 10 Shi, H, Hugo, W, Kong, X, et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov 4 (2014), 80–93.
11. 11 Trunzer, K, Pavlick, AC, Schuchter, L, et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol 31 (2013), 1767–1774.
12. V600-mutated melanoma: a phase 1b study. Lancet Oncol 15 (2014), 954–965.
13. 13 Larkin, J, Ascierto, PA, Dreno, B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 371 (2014), 1867–1876.
14. 14 Balch, CM, Gershenwald, JE, Soong, SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27 (2009), 6199–6206.
15. 15 Bucheit, AD, Syklawer, E, Jakob, JA, et al. Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma. Cancer 119 (2013), 3821–3829.
16. 16 Long, GV, Stroyakovskiy, D, Gogas, H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 371 (2014), 1877–1888.
17. 17 Long, GV, Stroyakovskiy, D, Gogas, H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 386 (2015), 444–451.
18. 18 Robert, C, Karaszewska, B, Schachter, J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372 (2015), 30–39.
19. 19 Eisenhauer, EA, Therasse, P, Bogaerts, J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 (2009), 228–247.
20. 20 Ishibashi, H, Suzuki, T, Suzuki, S, et al. Sex steroid hormone receptors in human thymoma. J Clin Endocrinol Metab 88 (2003), 2309–2317.
21. 21 Aaronson, NK, Ahmedzai, S, Bergman, B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85 (1993), 365–376.
22. 22 Ascierto, PA, Ipilimumab in the treatment of metastatic melanoma: a summary of recent studies. Tumori 99 (2013), 302e–305e.
23. 23 Diem, S, Prognostic score for patients with advanced melanoma treated with ipilimumab. Eur J Cancer 51 (2015), 2785–2791.
24. 24 Robert, C, Karaszewska, B, Schachter, J, et al. Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma. Eur J Cancer, 51, 2015, S663.
25. 25 Kelderman, S, Heemskerk, B, van, TH, et al. Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol Immunother 63 (2014), 449–458.
26. 26 Pavlick, AC, Ribas, A, Gonzalez, R, Hamid, O, Extended follow-up results of phase Ib study (BRIM7) of vemurafenib (VEM) with cobimetinib (COBI) in BRAF-mutant melanoma. J Clin Oncol, 33(15 suppl), 2015 abstr 9020.
27. 27 Dreno B, Ribas A, Larkin J, et al. Incidence, course, and management of toxicities associated with vemurafenib and cobimetinib in the coBRIM study. Society for Melanoma Research 2014; Zurich, Switzerland; Nov 13–16, 2014.
28. 28 Yan, Y, McArthur, G, Gajewski, T, et al. Vemurafenib and cobimetinib potently inhibit PS6 signaling in BRAFV600 mutation-positive locally advanced or metastatis melanoma from BRIM7 study. Ann Oncol, 25(suppl 4), 2014, iv378.
29. 29 Zelboraf (vemurafenib) tablet for oral use (prescribing information), August, 2015, Genentech USA Inc, South San Francisco, CA, USA.
30. 30 Cotellic (cobimetinib) tablets, for oral use (prescribing information), November, 2015, Genentech Inc, South San Francisco, CA, USA.
31. 31 Cotellic 20 mg film-coated tablets (summary of product characteristics), June, 2016, Roche Registration Limited, Welwyn Garden City, UK.
32. 32 Zelboraf 240 mg film-coated tablets (summary of product characteristics), 2016, Roche Registration Limited, Welwyn Garden City, UK.